StockData
Revolution Medicines, Inc. logo

Revolution Medicines, Inc. (RVMD) stock

RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$159.82−2.87 (-1.76%)

Close on Nov 18, 2026Market cap $34.26BP/E –Yield –

Earnings

Revolution Medicines's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$197.60M
EPS, Q3 FY2026
-$1.90
Latest guidance
Issued
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Revolution Medicines's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$197.60M–-$1.90Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close––-$3.06Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close–––Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025after the close––-$1.12Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close––-$0.94Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close––-$0.81Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close––-$0.70Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Revolution Medicines's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
estimated non-cash stock-based compensation expenseFY2026$270.00M – $290.00M–RaisedAug 5, 2026
expected non-cash stock-based compensation expenseFY2026$270.00M – $290.00M–NewNov 4, 2026
GAAP operating expenseGAAPFY2026$2.10B – $2.20B–NewNov 4, 2026
GAAP operating expenseGAAPFY2026$2.10B – $2.20B–RaisedAug 5, 2026
GAAP operating expensesGAAPFY2026$1.70B – $1.80B$1.60B – $1.70BRaisedMay 6, 2026
non-cash stock-based compensation expenseFY2026$180.00M – $200.00M–NewFeb 25, 2026
stock-based compensation expenseFY2026$260.00M – $280.00M–RaisedMay 6, 2026

Guidance history

Every forecast Revolution Medicines put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026GAAP operating expenseFY2026$2.10B – $2.20BNew
Nov 4, 2026expected non-cash stock-based compensation expenseFY2026$270.00M – $290.00MNew
Aug 5, 2026GAAP operating expenseFY2026$2.10B – $2.20BRaised
Aug 5, 2026estimated non-cash stock-based compensation expenseFY2026$270.00M – $290.00MRaised
May 6, 2026stock-based compensation expenseFY2026$260.00M – $280.00MRaised
May 6, 2026GAAP operating expensesFY2026$1.70B – $1.80BRaised
Feb 25, 2026GAAP operating expensesFY2026$1.60B – $1.70BNew
Feb 25, 2026non-cash stock-based compensation expenseFY2026$180.00M – $200.00MNew
Nov 5, 2025GAAP net lossFY2025$1.03B – $1.09BRaised
Nov 5, 2025estimated non-cash stock-based compensation expenseFY2025$115.00M – $130.00MNew
Aug 6, 2025GAAP net lossFY2025-$1.09B – -$1.03BNew
May 7, 2025GAAP net lossFY2025$840.00M – $900.00MReaffirmed
May 7, 2025estimated non-cash stock-based compensation expenseFY2025$115.00M – $130.00MNew
Feb 26, 2025GAAP net lossFY2025$840.00M – $900.00MNew
Nov 6, 2024GAAP net lossFY2024-$600.00M – -$560.00MLowered
Nov 6, 2024estimated non-cash stock-based compensation expenseFY2024$70.00M – $80.00MReaffirmed
Aug 7, 2024GAAP net lossFY2024$560.00M – $600.00MRaised
Aug 7, 2024estimated non-cash stock-based compensation expenseFY2024$70.00M – $80.00MReaffirmed
May 8, 2024GAAP net lossFY2024$480.00M – $520.00MReaffirmed
May 8, 2024estimated non-cash stock-based compensation expenseFY2024$70.00M – $80.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Revolution Medicines filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Update
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?